Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Generate Biomedicines, Inc.NASDAQ: GENB

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital of -$30.65M in Q1 FY2026

Q1 FY2026 change in working capital was -$30.65M.

Context

  • Change in working capital amounted to 45.8% of revenue in FY2025, down 91.6 pp from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$30.65M— QoQ
Last fiscal yearDec 2025
-$14.62M-152.0% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-152.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(14.62M) USD
Year-over-year change
-152.0%

Change in Working Capital vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 change in working capital of $14.62M is the 3rd largest of the 5 companies compared; the peer median is $16.87M.
  • Its year-over-year change of -152.0% is the 4th highest of 5, against a peer median of -103.6%.
  • Change in working capital amounts to 45.8% of revenue for GENB, versus a peer median of 39.4%.
GENB Competitors Peer median
Change in Working Capital for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$58.2M -455.5%—58.4%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$19.93M -141.4%—1532.9%
GENBGenerate Biomedicines, Inc.FY2025$14.62M -152.0%—45.8%
ABCLAbCellera Biologics Inc.LTM Sep 2026$13.81M -65.8%—20.3%
ABSIAbsci CorporationLTM Mar 2026$81K +108.6%—4.4%
Peer median (excluding GENB) $16.87M-103.6%—39.4%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.